✦ LIBER ✦

Targets of a protease inhibitor, KNI-272, in HIV-1-infected cells

✍ Scribed by Toshiyuki Goto; Takashi Nakano; Takehiro Kohno; Shinichi Morimatsu; Chizuko Morita; Wu Hong; Yoshiaki Kiso; Masuyo Nakai; Kouichi Sano

Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 204 KB
Volume: 63
Category: Article
ISSN: 0146-6615
DOI: 10.1002/1096-9071(200103)63:3<203::aid-jmv1001>3.0.co;2-f

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Physiologically based pharmacokinetics o

Physiologically based pharmacokinetics of KNI-272, a tripeptide HIV-1 protease inhibitor

✍ Akiko Kiriyama; Tomoyuki Nishiura; Hirokazu Yamaji; Kanji Takada 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

The effects of dose on the pharmacokinetic characteristics of KNI-272 were evaluated in rats after intravenous (iv) administration. The plasma kinetics of KNI-272 were dose-independent within a dose range of 1.0 to 10.0 mg/kg. However, when the dose was increased to 50.0 mg/kg, the area under the pl

Conformational analysis of HIV-1 proteas

Conformational analysis of HIV-1 protease inhibitors: 2. Thioproline P1? Residue in the potent inhibitor KNI-272

✍ Murcko, Mark A.; Rao, B. Govinda; Gomperts, Roberto 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB 👁 2 views

does not contain a basic amine as do Saquinovir and JG-365, for example it should be easier to desolvate, which also assists in binding. The relationship between KNI-272, JG-365, Saquinovir, and P X proline-containing substrate also is 1

Absorption of new HIV-1 protease inhibit

Absorption of new HIV-1 protease inhibitor, KNI-272, after intraduodenal and intragastric administrations to rats: Effect of solvent

✍ M. Sugahara; A. Kiriyama; Y. Hamada; Y. Kiso; K. Takada 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB

KNI-272 is a tripeptide drug that has a strong pharmacological potential for treating human immunodeficiency virus type 1 (HIV-1). We have already reported the pharmacokinetic characteristics of KNI-272 after intravenous and intraduodenal (ID) administrations to rats. In this study, KNI-272 was admi

Pharmacokinetic study of a tripeptide HI

Pharmacokinetic study of a tripeptide HIV-1 protease inhibitor, KNI-174, in rats after intravenous and intraduodenal administrations

✍ Dr A. Kiriyama; T. Mimoto; Y. Kiso; K. Takada 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB

## Abstract Recently, as a new type of anti‐AIDS drug, an HIV‐1 protease inhibitor, KNI‐174, has been synthesized; it shows a potent and selective HIV‐1 protease inhibitory activity __in vitro__. In this study, we developed an HPLC assay system for KNI‐174 in rat plasma and examined the pharmacokin

Bioanalysis of Syn Dimeric HIV-1 Proteas

Bioanalysis of Syn Dimeric HIV-1 Protease Inhibitor N-Benzyl 4-Aryl-1,4-dihydropyridine H19: Metabolic and Cytotoxic Properties in Hep G2 Cells

✍ Andreas Hilgeroth; Andreas Langner 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB 👁 1 views

Unintegrated HIV-1 circular 2-LTR provir

Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: Relative effect of recombinant CD4, zidovudine, and saquinavir in vitro

✍ Panther, Lori A.; Coombs, Robert W.; Aung, Sandra A.; dela Rosa, Corazone; Gretc 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 353 KB 👁 1 views

Unintegrated HIV-1 proviral DNA is one of the earliest detectable forms of HIV-1, and the influence of an antiretroviral drug on its appearance may reflect the efficacy of that agent in preventing infection of new cells. We characterized the dynamics of HIV-1 p24 (p24) antigen production, HIV-1 gag